参考文献/References:
[1] Leiter LA,Cariou B,Müller-Wieland D,et al.Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN randomized trial[J].Diabetes Obes Metab,2017,19(12):1781-1792.DOI:10.1111/dom.13114.
[2] Khavandi M,Duarte F,Ginsberg HN,et al.Treatment of dyslipidemias to prevent cardiovascular disease in patients with type 2 diabetes[J].Curr Cardiol Rep,2017,19(1):7.DOI:10.1007/s11886-017-0818-1.
[3] Newman JD,Schwartzbard AZ,Weintraub HS,et al.Primary prevention of cardiovascular disease in diabetes mellitus[J].J Am Coll Cardiol,2017,70(7):883-893.DOI:10.1016/j.jacc.2017.07.001.
[4] Scicali R,Di Pino A,Ferrara V,et al.New treatment options for lipid-lowering therapy in subjects with type 2 diabetes[J].Acta Diabetol,2018,55(3):209-218.DOI:10.1007/s00592-017-1089-4.
[5] Jellinger PS,Handelsman Y,Rosenblit PD,et al.American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease[J].Endocr Pract,2017,23(suppl 2):1-87.DOI:10.4158/ep171764.appgl.
[6] Melendez QM,Krishnaji ST,Wooten CJ,et al.Hypercholesterolemia: the role of PCSK9[J].Arch Biochem Biophys,2017,625-626:39-53.DOI:10.1016/j.abb.2017.06.001.
[7] Da Dalt L,Ruscica M,Bonacina F,et al.PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor[J].Eur Heart J,2019,40(4):357-368.DOI:10.1093/eurheartj/ehy357.
[8] Momtazi AA,Banach M,Pirro M,et al.PCSK9 and diabetes: is there a link?[J].Drug Discov Today,2017,22(6):883-895.DOI:10.1016/j.drudis.2017.01.006.
[9] Di Taranto MD,Benito-Vicente A,Giacobbe C,et al.Identification and in vitro characterization of two new PCSK9 gain of function variants found in patients with familial hypercholesterolemia[J].Sci Rep,2017,7(1):15282.DOI:10.1038/s41598-017-15543-x.
[10] 刘宁,旦菊花,李秋霞,等.前蛋白转化酶枯草溶菌素9抑制剂降低血清LDL-C的作用机制及临床疗效[J].基础医学与临床,2018,38(9):1342-1347.
[11] Farnier M.PCSK9:from discovery to therapeutic applications[J].Arch Cardiovasc Dis,2014,107(1):58-66.DOI:10.1016/j.acvd.2013.10.007.
[12] Rashid S,Curtis DE,Garuti R,et al.Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9[J].Proc Natl Acad Sci U S A,2005,102(15):5374-5379.DOI:10.1073/pnas.0501652102.
[13] Costet P,Cariou B,Lambert G,et al.Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c[J].J Biol Chem,2006,281(10):6211-6218.DOI:10.1074/jbc.M508582200.
[14] Lagace TA,Curtis DE,Garuti R,et al.Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice[J].J Clin Invest,2006,116(11):2995-3005.DOI:10.1172/JCI29383.
[15] Schwartz GG,Szarek M,Bhatt DL,et al. The ODYSSEY OUTCOMES trial:Topline Results Alirocumab in patients after acute coronary syndrome[C]. Orlando:American College of Cardiology-67 th Scientific Sessions,2018,March 10.
[16] de Carvalho LSF,Campos AM,Sposito AC.Proprotein convertase subtilisin/Kexin type 9(PCSK9)inhibitors and incident type 2 diabetes: a systematic review and meta-analysis with over 96,000 patient-years[J].Diabetes Care,2018,41(2):364-367.DOI:10.2337/dc17-1464.
[17] Cao YX,Liu HH,Dong QT,et al.Effect of proprotein convertase subtilisin/kexin type 9(PCSK9)monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: a systematic review and meta-analysis[J].Diabetes Obes Metab,2018,20(6):1391-1398.DOI:10.1111/dom.13235.
[18] Ray KK,Leiter LA,Müller-Wieland D,et al.Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: the ODYSSEY DM-DYSLIPIDEMIA randomized trial[J].Diabetes Obes Metab,2018,20(6):1479-1489.DOI:10.1111/dom.13257.
[19] Sabatine MS,Giugliano RP,Keech AC,et al.Evolocumab and clinical outcomes in patients with cardiovascular disease[J].N Engl J Med,2017,376(18):1713-1722.DOI:10.1056/NEJMoa1615664.
[20] Erqou S,Lee CC,Adler AI.Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis[J].Diabetologia,2014,57(12):2444-2452.DOI:10.1007/s00125-014-3374-x.
[21] Sabatine MS,Leiter LA,Wiviott SD,et al.Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial[J].Lancet Diabetes Endocrinol,2017,5(12):941-950.DOI:10.1016/S2213-8587(17)30313-3.
[22] Sabatine MS,Giugliano RP,Wiviott SD,et al.Efficacy and safety of evolocumab in reducing lipids and cardiovascular events[J].N Engl J Med,2015,372(16):1500-1509. DOI:10.1056/NEJMoa1500858.
[23] 诸骏仁, 高润霖, 赵水平,等. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志,2016,31(10): 937-953.DOI:10.3969/j.issn.1000-3614.2016.10.001.
相似文献/References:
[1]李春睿,王静,陈峰,等.GLP-1受体激动剂对糖尿病患者肾功能的影响[J].国际内分泌代谢杂志,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
Li Chunrui*,Wang Jing,Chen Feng,et al.Effects of GLP-1 receptor agonists on renal function of diabetics[J].International Journal of Endocrinology and Metabolism,2014,(04):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
[2]黄珊珊,鲁一兵.长链非编码RNA与糖尿病[J].国际内分泌代谢杂志,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
Huang Shanshan*,Lu Yibing..Long non-coding RNA and diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
[3]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(04):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[4]郑佳,肖新华.葡萄糖稳态的中枢调控作用机制
——2014年美国糖尿病协会“杰出科学成就奖”
演讲报告解读[J].国际内分泌代谢杂志,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
Zheng Jia,Xiao Xinhua.The mechanisms of central nervous system in the control of glucose homeostasis--A summary of 2014 ADA "Outstanding Scientific Achievement Award" Lecture[J].International Journal of Endocrinology and Metabolism,2014,(04):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
[5]唐勤,邵莉.蛋白乙酰化与胰岛素分泌[J].国际内分泌代谢杂志,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
Tang Qin,Shao Li..Protein acetylation and insulin secretion[J].International Journal of Endocrinology and Metabolism,2014,(04):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
[6]卢婷婷,任思佳,沈捷.人群迁徙对糖尿病患病率的影响及其相关因素[J].国际内分泌代谢杂志,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
Lu Tingting,Ren Sijia,Shen Jie..Impact of migration on prevalence of diabetes and risk factors[J].International Journal of Endocrinology and Metabolism,2014,(04):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
[7]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(04):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
[8]孟庆冬,陶红.巨噬细胞凋亡与糖尿病动脉粥样硬化[J].国际内分泌代谢杂志,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
Meng Qingdong,Tao Hong..Macrophage apoptosis and diabetic atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(04):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
[9]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(04):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[10]吕丹 李晓思 陈树春 王泽普.Betatrophin:糖尿病再生治疗的新希望[J].国际内分泌代谢杂志,2015,(05):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]
Lyu Dan*,Li Xiaosi,Chen Shuchun,et al.Betatrophin:new hope for regeneration therapy of diabetes[J].International Journal of Endocrinology and Metabolism,2015,(04):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]